PT-141 Melanocortin Research Protocol Design
In published preclinical and clinical research examining PT-141 (bremelanotide), study designs have focused on melanocortin receptor pharmacology, hypothalamic activation characterization, and relevant physiological endpoint assessment. The research literature documents central nervous system-mediated mechanisms distinct from peripherally-acting compounds studied for related endpoints. Published protocols include both animal model designs using c-Fos immunohistochemistry and clinical trial designs leading to 2019 FDA approval. Cardiovascular parameter monitoring is a documented standard component of published research protocol designs for this compound.
Research Reference Only: This page documents how research protocols appear in published scientific literature. All content is for in vitro research reference only and does not constitute guidance for human use or experimentation.
Study Design Types in Published Literature
How published researchers have structured studies in this research area.
Melanocortin Receptor Binding Studies
Published in vitro pharmacology has used radioligand binding assays and functional cAMP measurement to characterize PT-141 affinity and selectivity across melanocortin receptor subtypes MC1R through MC5R. Study designs document IC50 values, selectivity ratios, and cAMP dose-response curves as primary pharmacological endpoints.
Common Endpoints
- •Radioligand binding IC50 at MC3R and MC4R
- •cAMP production concentration-response
- •Receptor selectivity ratio calculations
- •Functional agonist potency comparison
Hypothalamic c-Fos Activation Studies
Published animal neuroanatomy research has examined PT-141-induced hypothalamic activation using c-Fos immunohistochemistry as a neuronal activation marker. Study designs characterize which hypothalamic nuclei show dose-dependent c-Fos induction following central receptor activation.
Common Endpoints
- •c-Fos immunopositive cell counting by region
- •Paraventricular nucleus activation
- •Medial preoptic area activation
- •Dose-response activation quantification
Cardiovascular Monitoring Protocols
Published clinical research has documented blood pressure monitoring as a standard protocol component for PT-141 studies. Clinical trial designs included pre-administration cardiovascular screening, intravenous access for monitoring, and post-administration blood pressure assessment at defined intervals as published in clinical methodology.
Common Endpoints
- •Systolic and diastolic blood pressure
- •Heart rate monitoring
- •Time course of cardiovascular changes
- •Safety event documentation
Clinical Pharmacology Studies
Phase II and III clinical trial designs leading to FDA approval included placebo-controlled, double-blind parallel group designs. Published clinical methodology used patient-reported outcome instruments and physiological assessment endpoints with pre-specified analysis of primary and secondary endpoints.
Common Endpoints
- •Patient-reported outcome instruments
- •Dose-response efficacy metrics
- •Safety and tolerability assessment
- •Pharmacokinetic characterization
Values from Published Preclinical Literature
Parameters documented in published research. These are literature values from specific model systems, not recommendations.
| Parameter | Published Value | Source |
|---|---|---|
| Clinical Dose Range in Published Trials | 0.75 to 3 mg in published Phase II dose escalation; 1.75 mg in FDA-approved Phase III design | Published PT-141 clinical trial methodology and FDA approval documentation |
| Animal Model Dose Range | 0.01 to 1 mg per kg in published rodent pharmacology studies | Published PT-141 preclinical pharmacology literature |
| Blood Pressure Monitoring Interval | Pre-administration and at 30, 60, and 120 minutes post-administration in published clinical protocols | Published PT-141 clinical trial safety monitoring documentation |
| Administration Route in Published Clinical Studies | Subcutaneous injection in published clinical trials; intranasal delivery examined in earlier published research | Published PT-141 clinical development literature |
| Time to Onset in Published Pharmacodynamic Studies | 30 to 60 minutes to pharmacodynamic effect onset documented in published pharmacokinetic studies | Published PT-141 pharmacokinetic characterization |
Research Considerations in Published Protocols
- 1
Published clinical protocols document blood pressure monitoring as a required safety component; protocol design should incorporate cardiovascular parameter assessment
- 2
PT-141 is contraindicated in published protocols for subjects with cardiovascular disease per FDA-approved labeling, informing subject selection criteria in research designs
- 3
c-Fos methodology in published animal studies uses 2-hour timepoint standardization for peak nuclear translocation detection after administration
- 4
Receptor selectivity documentation in published literature uses standardized panel assays; researchers should consult published selectivity data before designing receptor-focused studies
- 5
Clinical outcome measurement instruments used in published PT-141 trials have been validated and are documented in published clinical development methodology
Related Research
Frequently Asked Questions
Source Research Compounds
Spartan Peptides supplies research-grade compounds at least 98% HPLC-verified purity with Certificate of Analysis documentation. Domestic US supply, same-day dispatch before 2 PM.
For in vitro research use only. Not for human consumption or experimentation.